Managers / Q3 2022 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $277M in U.S.-listed holdings across 15 positions for Q3 2022.
Its largest position, ARWR, represents 14.5% of the portfolio.
Compared with Q2 2022, the fund opened 2 new positions and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 59.4% · $165M
- Other · 15.9% · $44M
- ETP · 14.3% · $40M
- ADR · 10.5% · $29M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SLNSILENCE THERAPEUTICS PLC | NEW | +1.26M | 1.26M | +$13M | $13M |
| KYMRKYMERA THERAPEUTICS INC | NEW | +330.2K | 330.2K | +$7M | $7M |
| FDMT4D MOLECULAR THERAPEUTICS IN | TRIMMED | −858.0K | 3.6K | −$6M | $29,000 |
| SPROSPERO THERAPEUTICS INC | TRIMMED | −1.92M | 3.40M | +$3M | $7M |
| XBIS&P BIOTECH ETF TR | TRIMMED | −250.0K | 500.0K | −$16M | $40M |
| BLUEPRINT MEDICINES CORP | TRIMMED | −192.3K | 524.3K | −$2M | $35M |
| RGNXREGENXBIO INC | TRIMMED | −200.0K | 967.7K | −$3M | $26M |
| GMABGENMAB A/S | ADDED | +30.0K | 244.8K | +$887,000 | $8M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 14.52% | $40M | 1.22M |
| 2 | BLUEPRINT MEDICINES CORP | COM | 12.45% | $35M | 524.3K |
| 3 | MERUS N V | COM | 10.88% | $30M | 1.51M |
| 4 | ARVNARVINAS INChistory → | COM | 10.77% | $30M | 671.7K |
| 5 | RGNXREGENXBIO INChistory → | COM | 9.22% | $26M | 967.7K |
| 6 | QUREUNIQURE NVhistory → | SHS | 5.69% | $16M | 841.5K |
| 7 | AMRYT PHARMA PLC | SPONSORED ADS | 4.99% | $14M | 2.00M |
| 8 | SLNSILENCE THERAPEUTICS PLChistory → | ADS | 4.57% | $13M | 1.26M |
| 9 | ARGXARGENX SEhistory → | SPONSORED ADR | 3.05% | $8M | 24.0K |
| 10 | GMABGENMAB A/Shistory → | SPONSORED ADS | 2.84% | $8M | 244.8K |
| 11 | KYMRKYMERA THERAPEUTICS INChistory → | COM | 2.59% | $7M | 330.2K |
| 12 | SPROSPERO THERAPEUTICS INChistory → | COM | 2.45% | $7M | 3.40M |
| 13 | PIERIS PHARMACEUTICALS INC | COM | 1.67% | $5M | 4.04M |
| 14 | FDMT4D MOLECULAR THERAPEUTICS IN | COM | 0.01% | $29,000 | 3.6K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.